US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

42.72

+1.072.57%

Pre-market: 42.990.2700+0.63%07:53 EDT

Volume:219.40K

Turnover:9.26M

Market Cap:318.26M

PE:- -

High:42.86

Open:41.64

Low:41.44

Close:41.65

52wk High:42.97

52wk Low:23.90

Shares:7.45M

Float Shares:7.45M

Volume Ratio:0.69

T/O Rate:2.94%

Dividend:0.28

Dividend Rate:0.66%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says

MT Newswires Live

Moderna up over 7%, on Track for Highest Close Since January 2023

Truist sees ‘significant positive readthrough’ for Maze from Vertex data

Maze jumps 25% to $27.99 after Vertex kidney disease data

Why Is Viking Therapeutics Stock (VKTX) Up 32% Today?

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)

Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria

Press Release: Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

Forge Nano and Nanexa to Develop Gmp-Compatible Ald Manufacturing Equipment

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live

Incyte Posts 24-Week TRuE-AD4 Data on Long-Term Safety of Ruxolitinib Cream in Moderate Atopic Dermatitis at EADV 2026

Nanexa, Forge Nano Enter Joint Development Deal on GMP-Scale ALD Equipment for PharmaShell Injectables

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria

Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria

THOMSON REUTERS

Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts

THOMSON REUTERS

Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/IDNA/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":42.72,"timestamp":1791230400000,"preClose":41.65,"halted":0,"volume":219396,"hourTrading":{"tag":"盘前","latestPrice":42.99,"preClose":42.72,"latestTime":"07:53 EDT","volume":101,"amount":4333.62013,"timestamp":1791287587550,"change":0.27,"changeRate":0.00632,"amplitude":0.00632},"delay":0,"changeRate":0.025690276110444187,"floatShares":7450000,"shares":7450000,"eps":0,"marketStatus":"Pre-Mkt","change":1.07,"latestTime":"10-06 08:15:03 EDT","open":41.64,"high":42.855,"low":41.44,"amount":9262746.200987998,"amplitude":0.033974,"askPrice":46.67,"askSize":100,"bidPrice":39.07,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791293400000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":42.72,"sharesOutstanding":5100000,"nav":41.483661,"aum":309297448.94,"dividendRate":0.006601,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":42.99,"preClose":42.72,"latestTime":"07:53 EDT","volume":101,"amount":4333.62013,"timestamp":1791287587550,"change":0.27,"changeRate":0.00632,"amplitude":0.00632},"postHourTrading":{"tag":"盘后","latestPrice":42.97,"preClose":42.72,"latestTime":"19:59 EDT","volume":2505,"amount":107179.02,"timestamp":1791244769975,"change":0.25,"changeRate":0.005852,"amplitude":0.005852},"volumeRatio":0.6860378810274388,"impliedVol":0.2456,"impliedVolPercentile":0.696},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":7450000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6860378810274388,"shares":7450000,"dividePrice":0.282,"high":42.855,"amplitude":0.033974,"preClose":41.65,"low":41.44,"week52Low":23.9,"pbRate":"--","week52High":42.97,"institutionHeld":0,"latestPrice":42.72,"eps":0,"divideRate":0.006601,"volume":219396,"delay":0,"ttmEps":0,"open":41.64,"prevYearClose":26.19,"prevWeekClose":41.65,"prevMonthClose":42.32,"prevQuarterClose":42.32,"fiveDayClose":41.79,"twentyDayClose":39.77,"sixtyDayClose":33.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669123074","title":"Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669123074","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669123074?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:45","pubTimestamp":1790091909,"startTime":"0","endTime":"0","summary":"Incyte's  colorectal cancer or CRC programs remain \"risky and more long-term,\" RBC Capital Markets said in a Tuesday note, while expectations for upcoming pancreatic cancer data remain elevated.The company is set to present data on its oncology programs at the upcoming European Society for Medical Oncology or ESMO Congress, with investors expecting improved efficacy from its '734 KRAS G12D inhibitor. Incyte is evaluating '734 in CRC and pancreatic ductal adenocarcinoma or PDAC, while its '890 program is being studied in CRC, according to the note.For PDAC, RBC expects overall response rates or ORR to exceed 80%, compared with 82% for rival zoldonrasib, while the brokerage said the two therapies have appeared comparable on efficacy and that safety could be a differentiating factor longer term.In CRC, RBC said its KOL feedback suggests ORR could range from 45% to 70%, while an ORR in the 80s would be needed to give the community greater comfort in eventual translation to survival.RBC has","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4532","BK4585","BK4139","INCY","IDNA","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669123650","title":"Moderna up over 7%, on Track for Highest Close Since January 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2669123650","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669123650?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:12","pubTimestamp":1790089920,"startTime":"0","endTime":"0","summary":"Moderna, Inc.  is currently at $186.54, up $13.60 or 7.86%--Would be highest close since Jan. 27, 2023, when it closed at $189.35--On pace for largest percent increase since Sept. 21, 2026, when it rose 12.27%--Currently up four of the past five days--Currently up two consecutive days; up 21.1% over this period--Best two day stretch since the two days ending Aug. 20, 2026, when it rose 111.75%--Up 32.92% month-to-date--Up 532.55% year-to-date--Down 61.5% from its all-time closing high of $484.47 on Aug. 9, 2021--Up 623.3% from 52 weeks ago , when it closed at $25.79--Would be a new 52-week closing high--Up 734.26% from its 52-week closing low of $22.36 on Nov. 20, 2025--Traded as high as $187.19; highest intraday level since Jan. 30, 2023, when it hit $187.59--Up 8.24% at today's intraday high--Best performer in the S&P 500 todayAll data as of 11:09:38 AM ETSource: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MRNA","IDNA","BK4588","MRNX","BK4585","GNOM","BK4532","BK4548","LGHT","WDNA","BK4568","BK4533","BK4551","BK4501","MRNY","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669128999","title":"Truist sees ‘significant positive readthrough’ for Maze from Vertex data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669128999","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669128999?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:30","pubTimestamp":1790087413,"startTime":"0","endTime":"0","summary":"Truist analyst Danielle Brill views Vertex’s (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL1-m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-positive-readthrough-for-maze-from-vertex-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/truist-sees-significant-positive-readthrough-for-maze-from-vertex-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERX","IE00BJJMRZ35.SGD","LU0058720904.USD","LU0061475181.USD","BK4585","IE00BZ9MQY76.HKD","IE00B4R5TH58.HKD","LU1069344957.HKD","LU0320765992.SGD","LU0757428866.USD","LU0079474960.USD","LU2362540622.SGD","IE00B19Z3B42.SGD","IE0002141913.USD","LU0256863811.USD","IE00B19Z9P08.USD","TBXU","BK4533","LU1778281490.HKD","LU2456880835.USD","IE0002270589.USD","LU1093756325.SGD","LU1559883803.SGD","LU2462157665.USD","LU2089984988.USD","SGXZ57979304.SGD","BIB","IBB","IE00B894F039.SGD","LU0823416689.USD","SG9999013999.USD","IE00B19Z9Z06.USD","IBBQ","LU1674673691.USD","IE0009355771.USD","LU0289739699.SGD","GNMX","VRTX","LU1585245621.USD","LU1674673428.USD","LU1035775433.USD","LU0889565916.HKD","LU2362541513.USD","PBE","BK4023","IE00B19Z3581.USD","LU1093756168.USD","IDNA","BBH","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669919128","title":"Maze jumps 25% to $27.99 after Vertex kidney disease data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669919128","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669919128?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:25","pubTimestamp":1790087125,"startTime":"0","endTime":"0","summary":"10:23 EDT Maze jumps 25% to $27.99 after Vertex kidney disease data Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-jumps-25-to-27-99-after-vertex-kidney-disease-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-jumps-25-to-27-99-after-vertex-kidney-disease-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0234570918.USD","LU2089984988.USD","IE00B19Z9P08.USD","BK4139","IBBQ","LU1093756168.USD","BK4567","IBB","IDNA","IE00B894F039.SGD","IE00BJT1NW94.SGD","BIB","LU2456880835.USD","IE00BFTCPJ56.SGD","LU2462157665.USD","IE0002270589.USD","LU1585245621.USD","LU2362541273.HKD","VERX","BBH","LU0889565916.HKD","LU0320765992.SGD","LU2417539215.USD","BK4023","LU1778281490.HKD","LU0289739699.SGD","LU1559883803.SGD","LU1093756325.SGD","SG9999013999.USD","LU0256863811.USD","LU0058720904.USD","BK4585","BK4533","LU0432979614.USD","IE00B19Z3581.USD","LU0079474960.USD","LU2362541513.USD","SGXZ57979304.SGD","VRTX","IE0002141913.USD","LU2236285917.USD","IE0009355771.USD","IE00BZ9MQY76.HKD","TBXU","LU1815336091.USD","LU1674673428.USD","LU0109394709.USD","IE00B19Z9Z06.USD","GNMX","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669610140","title":"Why Is Viking Therapeutics Stock (VKTX) Up 32% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669610140","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669610140?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:58","pubTimestamp":1790085506,"startTime":"0","endTime":"0","summary":"Viking Therapeutics stock rallied more than 32% on Tuesday following a clinical trial update for weight loss drug VK2735.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-viking-therapeutics-stock-vktx-up-32-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-viking-therapeutics-stock-vktx-up-32-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VKTX","HYLG","THNR","BK4585","BK4139","MEDX","GDOC","NVIB","IDNA","BK4599","BK4588","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669472461","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669472461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669472461?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:30","pubTimestamp":1790083809,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lill...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-pyxis-oncology-pyxs-moderna-mrna-and-eli-lilly-co-lly-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-pyxis-oncology-pyxs-moderna-mrna-and-eli-lilly-co-lly-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0203201768.USD","LU2213496289.HKD","SG9999014914.USD","LU1551013425.SGD","MEDX","LU2552382058.USD","BK4581","LU2106854487.HKD","IE00BK4W5L77.USD","HRTS","LU0238689110.USD","LU1061106388.HKD","LU0203202063.USD","SG9999018857.SGD","MRNX","LU2271345857.HKD","LU2108987350.USD","LU0882574139.USD","LU0385154629.USD","LU1069344957.HKD","LU1267930730.SGD","IE00BN29S564.USD","LU1232071149.USD","LLYX","OZEM","LU2063271972.USD","LU1127390331.HKD","LU0354030511.USD","LU1064131342.USD","LU2168563687.JPY","LU0640476718.USD","LU2168564149.EUR","LU2237443465.HKD","LU0061475181.USD","LU2265009873.SGD","ELIS","IE00B1XK9C88.USD","LU0471298694.HKD","LU2462591350.SGD","PYXS","PPH","LU2023250330.USD","LU1868836757.USD","IE00BFTCPJ56.SGD","LU2756315664.SGD","LU0417517546.SGD","LU2237438978.USD","SG9999013999.USD","IE0002141913.USD","LU0786609619.USD","LU2112291526.USD","LU1868837136.USD","LU1814569148.SGD","LU2552382132.HKD","LU1712237335.SGD","FTXH","CANC","IE0004445015.USD","LU2168564222.USD","LU2468319806.SGD","BK4548","IE00BJT1NW94.SGD","SGXZ51526630.SGD","LU2491050154.USD","VHT","BK4532","LU0345770993.USD","LU0345770308.USD","SGXZ81514606.USD","LU0689472784.USD","GDOC","IE00B7KXQ091.USD","SG9999015986.USD","LU1548497426.USD","BK4568","LU2111349929.HKD","IE00BFSS7M15.SGD","LU0225283273.USD","LU0823434740.USD","SG9999018865.SGD","LU2324357040.USD","LU2417539215.USD","RXL","IXJ","LU2602419157.SGD","LU1280957306.USD","ELIL","MRNY","LU0466842654.USD","SGXZ31699556.SGD","LLYZ","LU1691799644.USD","LU0708995401.HKD","LU2023250504.SGD","LU0256863811.USD","LU0256863902.USD","CURE","LU0672654240.SGD","LU2746668461.USD","SG9999015945.SGD","LU1093756168.USD","LU2089283258.USD","LU2023251221.USD","IE0005OL40V9.USD","LU0964807845.USD","LU0823434583.USD","LU0432979614.USD","LU1720051108.HKD","LU0058720904.USD","LU0943347566.SGD","BK4533","SG9999014906.USD","IE00BJJMRY28.SGD","LU0354030438.USD","LU1323610961.USD","LU2491050071.SGD","BK4588","LU2028103732.USD","SGXZ99366536.SGD","WDNA","LU0158827948.USD","LU0174119429.USD","LU1291159041.SGD","LU0094547139.USD","IE00BFSS8Q28.SGD","LU0471298777.SGD","LU0109394709.USD","LU1988902786.USD","TRUH","LU0198837287.USD","LU1868837300.USD","LU1366192091.USD","LU2461242641.AUD","IE00B1BXHZ80.USD","LU0210536198.USD","LU2361044865.SGD","SGXZ57979304.SGD","BK4599","LU0133085943.USD","LGHT","FHLC","LU0122379950.USD","LU0114720955.EUR","LU1989771016.USD","IE00B4R5TH58.HKD","LU2360106947.USD","LU2462157665.USD","TMED","LU2237443622.USD","LU2211815571.USD","LU1623119135.USD","LU2089284900.SGD","LU2552382215.SGD","LU2361045086.USD","MHIP","IE00B2B36J28.USD","SG9999015952.SGD","SG9999017495.SGD","SG9999001176.SGD","LU0353189763.USD","LU0096364046.USD","LU0823416689.USD","LU1979441026.SGD","PJP","IE00BWXC8680.SGD","LU0289739699.SGD","LU0316494557.USD","LU2456880835.USD","IE00BKPKM429.USD","SG9999014898.SGD","BK4534","BK4139","LU2896262040.SGD","MEDI","IE0004445239.USD","LU0097036916.USD","IE00B775H168.HKD","LU2471134879.HKD","LU2471134952.CNY","LU0456855351.SGD","LU0266013472.USD","IE0009355771.USD","GNOM","AGNG","LU2237443549.SGD","BK4007","GB00BDT5M118.USD","LU0079474960.USD","LU1917777945.USD","LU0006306889.USD","IE00BJJMRX11.SGD","LU1974910355.USD","LU2237443895.HKD","LU2491049909.HKD","MRNA","LU1868836591.USD","LU2264538146.SGD","IE0001KFT4U8.USD","LLII","LU0323591593.USD","LU2087625088.SGD","LU0882574055.USD","IE00BK4W5M84.HKD","IHE","LU2471134796.USD","LU0106261372.USD","LU0109391861.USD","LU0320765992.SGD","LU0820562030.AUD","LU0889565916.HKD","LU2089984988.USD","BK4501","BK4585","LU0320765059.SGD","ILDR","LU1023059063.AUD","LU2357305700.SGD","LU0158827781.USD","LU2750360641.GBP","LU1629891620.HKD","THNR","LU0683600562.USD","LU2746668974.SGD","SG9999001176.USD","LU1551013342.USD","SG9999015978.USD","LU2236285917.USD","LU2756315318.SGD","LU2168564495.EUR","BK4551","IDNA","IE00BJLML261.HKD","LU0820561909.HKD","BK4516","JDOC","LLY","LU0820561818.USD","LU1145028129.USD","LU1804176565.USD","IYH","IE00BKDWB100.SGD","LU2237443382.USD","LU0234572021.USD","LU2471134523.USD","SG9999014880.SGD","LU0353189680.USD","LU1035775433.USD","LU1057294990.SGD","LU1720051017.SGD","LU1983299246.USD","LU2361044949.HKD","LU2750360997.AUD","LU2237443978.SGD","IE00B4JS1V06.HKD","LU1093756325.SGD","IE00BJJMRZ35.SGD","LU1868836914.USD","LU0787776722.HKD","LU2168564065.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142464","title":"Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR by -42.7% at Week 13 in AMKD with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142464?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:02","pubTimestamp":1790082154,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Vertex Pharmaceuticals Incorporated::*VERTEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2B AMPLIFIED STUDY OF INAXAPLIN IN ADDITIONAL POPULATIONS OF PEOPLE WITH APOL1-MEDIATED KIDNEY DI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSD66vtCD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","LU0256863811.USD","GNMX","TBXU","LU2468319806.SGD","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD","IE00BZ9MQY76.HKD","LU1035775433.USD","LU2362541513.USD","LU0079474960.USD","PBE","SG9999013999.USD","LU2089984988.USD","LU2362540622.SGD","LU2417539215.USD","LU0417517546.SGD","IE0009355771.USD","BK4533","BK4567","BK4585","LU1093756325.SGD","BK4139","IE00BFTCPJ56.SGD","IBBQ","BIB","IE00B19Z9P08.USD","LU0823416689.USD","BK4532","LU0289739699.SGD","LU0889565916.HKD","VRTX","LU0234570918.USD","IDNA","IBB","LU2236285917.USD","LU2362541273.HKD","BK4588","LU0432979614.USD","LU1093756168.USD","SG9999001176.SGD","BBH","IE0002141913.USD","LU2237438978.USD","IE00B2B36J28.USD","IE00B19Z9Z06.USD","IE00B4R5TH58.HKD","LU1674673691.USD","IE00B894F039.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669739142","title":"Press Release: Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2669739142","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669739142?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082000,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (\"Optimi\" or the \"Company\"), a commercial-stage pharmaceutical manufacturer of","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","GDOC","IDNA","MEDX","OPTH","HYLG","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142210","title":"AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142210","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142210?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:55","pubTimestamp":1790081700,"startTime":"0","endTime":"0","summary":"Daraxonrasib is an important therapeutic advance, but pancreatic cancer is not a simple disease where one successful targeted drug makes additional therapeutic development unnecessary. We believe Ampligen has the potential to complement and extend therapies such as daraxonrasib by helping to overcome the immune biological barriers that have h","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366375/29489/en/aim-immunotech-highlights-ampligen-s-potential-role-in-the-evolving-pancreatic-cancer-treatment-landscape-following-fda-approval-of-revolution-medicines-daraxonrasib.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BBH","IE00BJJMRZ35.SGD","BK4588","LU0320765992.SGD","BK4585","IE0002141913.USD","IDNA","LU0109394709.USD","IE0009355771.USD","RVMD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE0009354923.USD","CANC","LABU","BK4139","PTH","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142551","title":"Forge Nano and Nanexa to Develop Gmp-Compatible Ald Manufacturing Equipment","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142551","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142551?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:52","pubTimestamp":1790081527,"startTime":"0","endTime":"0","summary":"Sept 22 (Reuters) - Nanexa AB::*FORGE NANO AND NANEXA TO DEVELOP GMP-COMPATIBLE ALD MANUFACTURING EQUIPMENT FOR PHARMASHELL PORTFOLIO*PORTFOLIO INCLUDES LICENSE AGREEMENT WITH MODERNA AND UNDISCLOSED ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nRSD6607P3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","GNOM","MRNY","BK4568","LGHT","BK4585","BK4533","BK4534","BK4551","BK4588","WDNA","MRNX","MRNA","BK4501","IDNA","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669425861","title":"Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669425861","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669425861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:50","pubTimestamp":1790081406,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.Shares of Vertex were up 2.2% pre-bell.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","IE0002141913.USD","LU0079474960.USD","LU1778281490.HKD","IE00B894F039.SGD","LU2468319806.SGD","GNMX","IBB","IE00BJT1NW94.SGD","BK4532","BK4567","LU2089984988.USD","BK4023","SGXZ57979304.SGD","IE00B19Z3581.USD","TBXU","IBBQ","LU1069344957.HKD","SG9999001176.USD","LU0566484027.USD","LU1815336091.USD","LU1559883803.SGD","LU2236285917.USD","LU2324357040.USD","LU2362540622.SGD","LU2417539215.USD","IE00B19Z9Z06.USD","IDNA","LU0757428866.USD","PBE","SG9999001176.SGD","LU1674673428.USD","LU0061475181.USD","VERX","IE00BZ9MQY76.HKD","BBH","LU1035775433.USD","LU1674673691.USD","LU2362541513.USD","BK4139","BIB","IE0002270589.USD","LU0058720904.USD","LU1093756325.SGD","BK4533","VRTX","IE00B19Z9P08.USD","IE00BJJMRZ35.SGD","SG9999013999.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144123","title":"Incyte Posts 24-Week TRuE-AD4 Data on Long-Term Safety of Ruxolitinib Cream in Moderate Atopic Dermatitis at EADV 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144123","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144123?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:32","pubTimestamp":1790080377,"startTime":"0","endTime":"0","summary":"Incyte posts 24-week TRuE-AD4 data on long-term safety of ruxolitinib cream in moderate atopic dermatitis at EADV 2026Incyte flagged new clinical and real-world data across its inflammation and autoim","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL7N04HG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","BK4532","BK4588","INCY","BK4585","BK4550","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669125144","title":"Nanexa, Forge Nano Enter Joint Development Deal on GMP-Scale ALD Equipment for PharmaShell Injectables","url":"https://stock-news.laohu8.com/highlight/detail?id=2669125144","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669125144?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:32","pubTimestamp":1790080347,"startTime":"0","endTime":"0","summary":"Nanexa, Forge Nano enter joint development deal on GMP-scale ALD equipment for PharmaShell injectablesNanexa entered a joint development agreement with Forge Nano to scale atomic layer deposition manu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL1PQdFL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","BK4551","BK4548","BK4585","IDNA","WDNA","MRNX","BK4532","BK4588","BK4534","GNOM","LGHT","BK4568","BK4533","BK4139","MRNA","BK4501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144047","title":"Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144047","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144047?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:30","pubTimestamp":1790080200,"startTime":"0","endTime":"0","summary":"New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Datase","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366329/0/en/propanc-biopharma-highlights-differentiated-prp-pancreatic-cancer-data-versus-emerging-pan-ras-program-eras-0015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYQNZ168.SGD","BK4512","BK4535","LU0109394709.USD","RVMD","BK4605","LU2298322129.HKD","BK4509","BK4565","LU0320765992.SGD","01698","IE0009354923.USD","ONG","LU1861220033.SGD","IDNA","TME","LU1023057109.AUD","LU1854103824.USD","PTH","IE0002141913.USD","LU0724618433.USD","LU1548497426.USD","LU0269904917.USD","LU1854104046.USD","ERAS","BK4139","LU0509642566.USD","LU1720051017.SGD","BK4141","PPCB","PDX","BK4585","CANC","LU2360107325.USD","IE00BYTNYN87.SGD","IE00BFTCPJ56.SGD","BK4531","BK4108","ON","IE00B12V2V27.USD","LU2357305700.SGD","BBH","BK4548","BK4571","IE00BJT1NW94.SGD","LU1861219969.SGD","BK4588","SG9999011746.SGD","LU0359202008.SGD","ONX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144313","title":"Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144313","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144313?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:15","pubTimestamp":1790079331,"startTime":"0","endTime":"0","summary":"The company states: “Vertex Pharmaceuticals (VRTX) announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1430594728.SGD","IE00B19Z3B42.SGD","IE00B19Z9Z06.USD","LU0432979614.USD","IE0009355771.USD","LU0109394709.USD","LU0061475181.USD","LU2362540622.SGD","LU2462157665.USD","TBXU","BK4567","LU1093756325.SGD","LU0320765992.SGD","LU2236285917.USD","LU2237438978.USD","LU1093756168.USD","IBBQ","LU1585245621.USD","LU0289739699.SGD","IDNA","IE00B2B36J28.USD","VERX","GNMX","LU0823416689.USD","IE0002141913.USD","BK4023","LU0757428866.USD","BK4139","LU1674673428.USD","BIB","LU0234570918.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","BK4532","IE00BFTCPJ56.SGD","LU1035775433.USD","LU1674673691.USD","IBB","LU1815336091.USD","SG9999001176.SGD","BBH","IE00BJT1NW94.SGD","LU0256863811.USD","BK4588","VRTX","LU1778281490.HKD","PBE","LU2089984988.USD","SG9999013999.USD","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669440251","title":"IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2669440251","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669440251?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:05","pubTimestamp":1790078700,"startTime":"0","endTime":"0","summary":"Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date No cytokine release syndrome, systemic toxi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366307/0/en/imunon-reports-independent-data-monitoring-committee-recommends-continued-phase-2-development-of-imnn-001-following-favorable-safety-review.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","IDNA","IMNN","BK4139","BK4211","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669177141","title":"Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669177141","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669177141?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:02","pubTimestamp":1790078577,"startTime":"0","endTime":"0","summary":"Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuriaVertex reported positive Phase 2b AMPLIFIED results for inaxaplin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL8CHhBr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","IBBQ","TBXU","IE00B19Z9P08.USD","LU0889565916.HKD","LU0823416689.USD","IE0002141913.USD","BK4532","PBE","LU0320765992.SGD","IE00BJT1NW94.SGD","IDNA","VRTX","BBH","LU1674673428.USD","BK4567","LU2462157665.USD","LU0061475181.USD","LU0109394709.USD","LU1035775433.USD","LU1069344957.HKD","LU2362541513.USD","IE00B2B36J28.USD","LU1093756325.SGD","LU0058720904.USD","LU0256863811.USD","IBB","BK4585","LU0079474960.USD","LU2089984988.USD","LU2468319806.SGD","IE00B19Z3581.USD","BIB","LU0432979614.USD","LU1093756168.USD","BK4588","SG9999013999.USD","IE00BFTCPJ56.SGD","LU1674673691.USD","BK4139","IE0002270589.USD","IE00B19Z9Z06.USD","GNMX","SG9999001176.SGD","LU2237438978.USD","SGXZ57979304.SGD","IE0009355771.USD","LU2362541273.HKD","IE00BZ9MQY76.HKD","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419861","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0009355771.USD","IE00B2B36J28.USD","LU1069344957.HKD","BBH","LU0109394709.USD","LU0234570918.USD","LU2362540622.SGD","IE0002270589.USD","LU0823416689.USD","LU0889565916.HKD","LU2237438978.USD","LU0417517546.SGD","LU2324357040.USD","LU2362541513.USD","LU2362541273.HKD","TBXU","IE0002141913.USD","LU2456880835.USD","IE00BJJMRZ35.SGD","LU0079474960.USD","LU2417539215.USD","PBE","IBB","BK4585","VRTX","BK4139","LU1093756325.SGD","IE00B19Z9Z06.USD","IBBQ","LU0289739699.SGD","LU1674673691.USD","LU2236285917.USD","LU2462157665.USD","SGXZ57979304.SGD","IE00B894F039.SGD","IDNA","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU1585245621.USD","LU0256863811.USD","IE00B19Z9P08.USD","LU1778281490.HKD","LU1430594728.SGD","LU2468319806.SGD","GNMX","BIB","SG9999001176.SGD","IE00B19Z3581.USD","LU1674673428.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419041","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419041?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBB","IE00BZ9MQY76.HKD","SG9999001176.USD","LU0889565916.HKD","LU1674673428.USD","IE00B19Z9P08.USD","LU2362541273.HKD","LU0109394709.USD","BK4532","LU2089984988.USD","BBH","BK4139","BK4567","LU0256863811.USD","LU1778281490.HKD","TBXU","LU0061475181.USD","IE0002141913.USD","SGXZ57979304.SGD","SG9999013999.USD","LU1585245621.USD","LU2237438978.USD","IDNA","LU2417539215.USD","IE00BJJMRZ35.SGD","LU0234570918.USD","GNMX","PBE","IE0002270589.USD","LU1069344957.HKD","IE00BJT1NW94.SGD","LU0432979614.USD","BK4533","LU1093756325.SGD","LU2324357040.USD","LU2462157665.USD","LU1035775433.USD","LU0058720904.USD","IBBQ","SG9999001176.SGD","VRTX","IE00B19Z9Z06.USD","BIB","LU0079474960.USD","BK4588","IE00B4R5TH58.HKD","LU0320765992.SGD","LU2362541513.USD","LU2456880835.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141954","title":"Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141954?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","IE00B19Z3B42.SGD","LU0432979614.USD","SGXZ57979304.SGD","LU2456880835.USD","LU0109394709.USD","IE0002270589.USD","LU0079474960.USD","LU0061475181.USD","TBXU","BK4567","LU1093756325.SGD","LU0320765992.SGD","LU2236285917.USD","LU0058720904.USD","LU2237438978.USD","LU1585245621.USD","IBBQ","LU0289739699.SGD","IDNA","IE00B2B36J28.USD","PBE","SG9999001176.USD","GNMX","LU0823416689.USD","IE0002141913.USD","IE00BZ9MQY76.HKD","BK4139","LU1674673428.USD","BK4585","BIB","LU0234570918.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","BK4532","LU1035775433.USD","SG9999001176.SGD","LU1674673691.USD","IBB","BBH","IE00BJT1NW94.SGD","LU0417517546.SGD","LU0256863811.USD","LU1069344957.HKD","VRTX","LU1778281490.HKD","BK4533","LU2089984988.USD","SG9999013999.USD","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}